ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells 5,400 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $71.00, for a total value of $383,400.00. Following the completion of the sale, the chief executive officer directly owned 339,089 shares of the company’s stock, valued at approximately $24,075,319. The trade was a 1.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nikhil Lalwani also recently made the following trade(s):

• On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $74.30, for a total value of $401,220.00.

ANI Pharmaceuticals Trading Up 2.1%

ANIP stock traded up $1.48 during trading on Wednesday, hitting $73.59. The company had a trading volume of 431,593 shares, compared to its average volume of 377,903. The business has a 50-day moving average of $76.69 and a 200-day moving average of $78.14. ANI Pharmaceuticals, Inc. has a one year low of $69.58 and a one year high of $98.55. The stock has a market cap of $1.69 billion, a PE ratio of 15.86 and a beta of 0.45. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company’s revenue was up 25.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ANIP. Arrowstreet Capital Limited Partnership grew its position in ANI Pharmaceuticals by 19.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after buying an additional 91,153 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of ANI Pharmaceuticals by 8.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after acquiring an additional 43,523 shares in the last quarter. Ranger Investment Management L.P. purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $28,406,000. Deutsche Bank AG bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $26,775,000. Finally, William Blair Investment Management LLC bought a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $21,372,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ANIP shares. Canaccord Genuity Group cut their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Guggenheim cut their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Finally, Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price objective for the company. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $105.57.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.